Tirzepatide reduces obstructive sleep apnea symptoms and associated risks
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep...
Read MoreOct 11, 2024
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep...
Read MoreOct 11, 2024
1. DaxibotulinumtoxinA-lanm 500U showed the greatest reduction in MAS scores in patients suffering...
Read MoreOct 10, 2024
1. In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced...
Read MoreOct 9, 2024
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group...
Read MoreOct 9, 2024
1. Double-dose ESWT to the gastrocnemius and soleus showed greater improvements in post-stroke...
Read MoreOct 8, 2024
1. In a cluster randomized clinical trial, electronic health record (EHR)-based intervention...
Read MoreOct 8, 2024
1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23...
Read MoreOct 8, 2024
1. In this randomized controlled trial, twice daily crinecerfont use was associated with reduced...
Read MoreOct 8, 2024
1. Just-in-time adherence support systems in gamified cognitive training should be applied when...
Read MoreOct 6, 2024
1. A higher body roundness index (BRI) trajectory is associated with an increased risk of...
Read MoreOct 5, 2024
1. A participant with amyotrophic lateral sclerosis (ALS) and severe dysarthria underwent surgical...
Read MoreOct 4, 2024
1. A history of mild traumatic brain injury (TBI) in healthy, middle-aged adults was associated...
Read MoreOct 4, 2024
1. In this randomized controlled trial, among patients with moderately to severely active...
Read MoreOct 4, 2024
1. In this randomized clinical trial, adults with an alcohol use disorder (AUD) receiving either...
Read MoreOct 2, 2024
1. Major cardiac events were significantly lower in the OCT-guided group compared to the...
Read MoreOct 2, 2024
1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and...
Read MoreOct 1, 2024
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant)....
Read MoreOct 1, 2024
1. In this randomized controlled trial, patients with metabolic syndrome who underwent...
Read MoreOct 1, 2024
1. In this randomized controlled trial, in patients diagnosed with migraine, it was found that...
Read MoreSep 26, 2024
1. Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and...
Read More